Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis (NORMALIZE)

NCT03988920 is registered in ClinicalTrials.gov with Ardelyx as lead sponsor.

NCT NCT03988920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03988920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis (NORMALIZE)
Lead sponsor
Ardelyx
Phase
Phase 4
Overall status
Completed
Start date
June 15, 2019
Completion date
July 31, 2021
Enrollment
172 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease, hyperphosphatemia